Does Anthem (Elevance Health) Cover Reclast (Zoledronic Acid)?

Reclast is the brand name for zoledronic acid 5 mg, an intravenous bisphosphonate approved for osteoporosis and Paget's disease of bone. A generic IV zoledronic acid 5 mg/100 mL solution is also available. This article covers the commercial-insurance version of the drug used for bone disease, not the higher-dose oncology formulation (Zometa) used for bone metastases and hypercalcemia of malignancy, which follows different coverage rules.

Anthem, now operating under the Elevance Health corporate name, generally covers zoledronic acid as a medical-benefit infusion when the FDA-labeled indication and dosing are met. But "generally covers" is not the same as "will approve your claim without friction." Most commercial payers, Anthem included, require prior authorization for infused specialty drugs, and many require documentation that a lower-cost oral bisphosphonate was tried first. Whether your specific plan enforces step therapy, which formulary tier applies, and what your copay will be are questions that depend on your exact plan document and cannot be answered generically for every Anthem member.

The direct answer, and its limits

Zoledronic acid (Reclast, and its generic equivalent) is FDA-approved for treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease of bone, dosed as a single 5 mg intravenous infusion once every 12 to 24 months depending on indication. Commercial insurers, including Anthem plans, typically place infused osteoporosis drugs on a medical benefit or specialty pharmacy tier and require prior authorization, often with evidence that a first-line oral bisphosphonate was tried, failed, or was contraindicated. What varies by specific Anthem product and state is the exact prior-authorization criteria, formulary tier, and cost-share amount, which is why the only way to get a reliable answer for your own coverage is to check your plan's current clinical policy bulletin, summary of benefits, or member portal, or call the number on your insurance card.

What is established, what is plausible, and what is not established here

Established from the FDA label: zoledronic acid's approved indications, the once-yearly (or once-every-24-months for prevention) dosing schedule, and the contraindication in patients with creatinine clearance below 35 mL/min, along with the recommendation to check calcium and vitamin D status before infusion.

Plausible, consistent with general commercial insurance practice, but not confirmed as Anthem-specific policy in this draft: that Anthem requires prior authorization and step therapy with an oral bisphosphonate, that the drug sits on a specialty tier, and that a two-level internal-then-external appeal process applies. These patterns are typical of how large commercial payers handle infused specialty drugs generally, but this article does not have a verified, current Anthem clinical policy bulletin or formulary document to cite for Anthem specifically. Treat these as reasonable expectations to prepare for, not confirmed rules.

Not established here: exact dollar figures for Anthem's specialty copay, exact PA turnaround times, and exact appeal deadlines. Cost-sharing and administrative timelines vary by plan type (HMO, PPO, HDHP, Medicare Advantage, Medicaid managed care), by state, and by plan year, and published list-price or cash-price figures move over time. Any number below should be verified against your current plan documents before you rely on it financially.

Reclast (zoledronic acid) is a once-yearly IV bisphosphonate that most commercial insurers, including Anthem, treat as a specialty medical-benefit drug requiring prior authorization; the drug is FDA-approved for osteoporosis and Paget's disease at a 5 mg dose given every 12 to 24 months, and it is contraindicated below a creatinine clearance of 35 mL/min. Whether a particular Anthem plan requires step therapy with an oral bisphosphonate first, and what the member's exact copay will be, depends on the specific plan and state, and should be confirmed directly with Anthem rather than assumed from a general description.

What Anthem's coverage process generally looks like for infused osteoporosis drugs

Because Reclast is administered by IV infusion in a clinic, hospital outpatient department, or infusion center, payers typically process it under the medical benefit rather than the retail pharmacy benefit. That distinction matters because medical-benefit cost-sharing is often calculated as a percentage coinsurance after the deductible rather than a flat pharmacy copay, and it means the infusing facility, not just the prescriber, may need its own authorization on file.

Documentation that payers commonly ask for before approving an infused bisphosphonate includes:

• A confirmed osteoporosis diagnosis (low bone density on DXA scan, or a history of fragility fracture)
• Baseline labs, typically serum calcium, vitamin D status, and a kidney function measure, given the drug's renal contraindication
• Evidence that an oral bisphosphonate was tried and failed, caused intolerable side effects, or was contraindicated, if the plan enforces step therapy
• A completed prior-authorization request from the prescribing provider

Anthem Medicaid managed-care and Medicare Advantage products can have different formulary and utilization-management rules than commercial PPO or HMO products from the same parent company. A rule that applies to one Anthem product line should not be assumed to apply to another.

A decision framework for figuring out where you stand

Use this sequence before assuming approval or denial either way. It is organized around what changes what you should do next, not around a fixed script.

1. Confirm which Anthem product you actually have. Commercial PPO/HMO, Medicare Advantage, and Medicaid managed care each run separate formularies and PA rules under the same brand name. Pull up your specific plan's current formulary or clinical policy document, or call member services and ask them to read you the policy for zoledronic acid, not just tell you "it's covered."

2. Ask directly whether step therapy applies to your plan, and what counts as satisfying it. If your plan requires an oral bisphosphonate trial first, ask what duration and what documentation your prescriber needs to submit. If you have already tried and failed an oral agent, get that captured in your chart before submitting, not only in an appeal letter later.

3. Identify whether you fall into a recognized step-therapy exception category. Commonly recognized exceptions across payers include esophageal disease that contraindicates oral bisphosphonates, documented GI intolerance, inability to follow oral dosing instructions (cognitive or physical impairment), or a new fracture that occurred while already on an oral bisphosphonate. If one applies to you, ask your prescriber to request a step-therapy exception rather than a standard PA, and to state the exception reason explicitly.

4. Check whether your clinical situation is time-sensitive. A patient starting zoledronic acid shortly after a hip fracture is in a different urgency category than a patient with stable osteopenia considering a switch from an oral agent. If there is a recent fragility fracture or hospitalization, ask whether an expedited/urgent PA pathway applies, since standard PA timelines can otherwise delay treatment.

5. If denied, get the denial reason in writing before drafting an appeal. Denials for "not medically necessary," "step therapy not completed," and "site of care not covered" require different responses. An appeal built around the wrong reason wastes the appeal window.

6. Ask about the generic before assuming brand pricing. Some plans place generic zoledronic acid on a lower cost-sharing tier than brand-name Reclast. Ask the prescriber to write the order for "zoledronic acid" to leave room for generic substitution at the infusion site.

7. Confirm the infusion site is in-network separately from confirming the drug is covered. A covered drug administered at an out-of-network facility can still generate a large balance bill.

Formulary tier and cost-sharing: what to verify, not assume

Specialty infused drugs are commonly placed on a higher formulary tier (often labeled Tier 4 or 5) than oral generics, which increases cost-sharing. Manufacturer list prices for brand-name Reclast and cash-pay rates at infusion centers vary and change over time; any specific dollar figure quoted to you should be treated as approximate and confirmed against a current price list or your plan's cost-estimator tool as of the date you are scheduling, not treated as a fixed number. If your plan uses coinsurance rather than a flat copay for medical-benefit infusions, your out-of-pocket cost will also depend on where you are in your deductible for the plan year, which is why scheduling an elective annual infusion later in the benefit year, after other medical spending has accumulated, can lower the amount you personally owe.

Some plans use copay accumulator or maximizer programs that prevent manufacturer copay-assistance dollars from counting toward your deductible or out-of-pocket maximum. Whether a specific Anthem plan uses one of these programs varies by state and plan type and should be confirmed before relying on a manufacturer savings card for budgeting purposes.

How zoledronic acid compares with other osteoporosis drugs in the treatment sequence

Payers generally position osteoporosis drugs in a rough hierarchy, and understanding where zoledronic acid sits helps explain why step therapy exists.

Oral bisphosphonates (alendronate, risedronate) are usually first-line and lowest-cost, and most plans expect a trial here before approving an infused option, absent a contraindication.

Zoledronic acid (Reclast) is commonly approved after oral bisphosphonate failure or intolerance, or in patients unable to follow oral dosing instructions. Large randomized trials in postmenopausal women (the HORIZON-PFT trial) and in patients recently treated for hip fracture (the HORIZON-RFT trial) reported substantial reductions in vertebral and hip fracture risk with once-yearly IV zoledronic acid compared with placebo, and the hip-fracture trial also reported a mortality benefit, one of few osteoporosis trials to do so. These are well-known, published NEJM trials; exact percentage figures are widely cited in guideline literature, but this draft could not verify a working link to the original publications, so any precise percentage quoted to a payer or patient should be checked against the primary publication before being used in clinical documentation.

Denosumab (Prolia), an injectable given every six months, is another common second-line option after oral bisphosphonate failure, with the specific concern that stopping denosumab is associated with rapid bone loss and rebound vertebral fracture risk, which is why discontinuation should be discussed with the prescriber rather than done unilaterally.

Romosozumab (Evenity) and the parathyroid hormone analogs (teriparatide, abaloparatide) are generally reserved for more severe osteoporosis or after failure of first- and second-line agents, and romosozumab carries a cardiovascular warning that payers often factor into stricter prior-authorization criteria.

For a patient who cannot tolerate oral bisphosphonates, zoledronic acid is a reasonable, well-studied second-line choice with the practical advantage of once-yearly dosing, but it is not automatically the next step for every patient; denosumab is frequently considered in parallel, and the choice between the two depends on kidney function, adherence concerns, and discontinuation risk, which is a discussion for the prescriber rather than something to decide from a coverage article.

If Anthem denies the claim

Commercial health plans, including Anthem products, are generally required to offer an internal appeal followed by the right to an external review by an independent review organization if the internal appeal is denied. Exact appeal deadlines, required forms, and expedited-review criteria vary by state and by plan type, so confirm the specific deadline and process stated in your own denial letter rather than relying on a generic timeframe.

Practical steps that tend to help across payers:

• Request a peer-to-peer review, where the prescriber speaks directly with the plan's medical director. This is often faster than a written appeal alone.
• Make sure GI intolerance, non-adherence risk, or contraindications are documented in office visit notes before the PA request is submitted, not only added retroactively in an appeal letter.
• Cite the specific clinical circumstance (recent fragility fracture, documented oral bisphosphonate failure, renal or GI contraindication) rather than a general statement that the drug is "medically necessary."
• If billing codes are the stated reason for denial, ask the billing office to confirm the infusion and drug codes submitted were correct; miscoding is a common and correctable cause of denial.

Manufacturer and patient assistance options

Manufacturer copay-assistance programs for brand-name Reclast have historically been available to commercially insured patients meeting eligibility criteria, and separate patient-assistance programs based on income have been available for uninsured or underinsured patients. These programs generally cannot be combined with government insurance (Medicare, Medicaid, Tricare, VA) under federal rules. Current eligibility criteria and award amounts change over time and should be confirmed directly with the manufacturer's program rather than assumed from prior published figures.

Special situations worth flagging to your prescriber

Recent hip fracture. Trial evidence supports starting IV zoledronic acid within a window after hip fracture repair to reduce subsequent fracture and mortality risk. If this applies to you, ask whether an expedited authorization pathway is available given the time-sensitive nature of secondary fracture prevention.

Glucocorticoid-induced osteoporosis. Patients on chronic corticosteroid therapy are a distinct population for whom bisphosphonate therapy is commonly recommended by rheumatology guidelines at defined fracture-risk thresholds; this is often the most straightforward category for prior authorization because the indication is well defined.

Male osteoporosis. Zoledronic acid is FDA-approved for increasing bone mass in men with osteoporosis, and the same general PA and step-therapy expectations apply as for postmenopausal osteoporosis.

Kidney function. Because zoledronic acid is contraindicated below a creatinine clearance of 35 mL/min, any patient with reduced kidney function should have this confirmed and discussed with the prescriber before authorization is even requested, since it affects candidacy for the drug at all, not just coverage.

When to seek urgent care rather than manage this by phone

None of the coverage or appeal steps above should delay urgent medical attention. Severe bone pain, a suspected new fracture, symptoms of severe hypocalcemia (muscle cramps, tingling around the mouth or fingers, seizures), or an acute allergic reaction after an infusion warrant immediate medical evaluation rather than working through an insurance appeal first.